CompletedNot Applicable

Follow-up Study to Assess Visual Function in Subset of Patients Who Have Previously Participated in the TG-MV-006 and TG-MV-007 Ocriplasmin Studies

United States, Belgium24 participantsStarted 2011-05

Plain-language summary

The primary objective of this study is to assess visual function in up to 44 patients who have previously participated in either of the placebo controlled, ocriplasmin Phase III studies (TG-MV-006 or TG-MV-007).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Written informed consent obtained from the patient prior to inclusion in the follow-up study * Previous participation in either of the placebo controlled, ocriplasmin Phase III studies (TG-MV-006 or TG-MV-007) Exclusion Criteria: * N/A

What they're measuring

Evidence of clinically significant abnormality in visual function, including Best Corrected Visual Acuity (BCVA), Spectral Domain Optical Coherence Tomography (SD-OCT) abnormality, and/or Electroretinography (ERG) abnormality

Timeframe: Visit 1

Trial details

NCT IDNCT01287988

SponsorThromboGenics

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2011-10

View on ClinicalTrials.gov More Symptomatic Vitreomacular Adhesion trials